

TAYSIDE PRESCRIBER

June 2008

Tayside DTC Supplement No 80Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

SMC Advice issued in June 2008

Medicine	Indication	Local recommendation category	Comments and useful links
Adalimumab (Humira [®])	Chronic plaque psoriasis	HOSPITAL ONLY - pending update of local guidelines on the biological treatment of psoriasis	SMC advice SPC link
Anidulafungin (Ecalta [®])	Invasive candidiasis	Not recommended	SMC advice
Bevacizumab (Avastin [®])	Metastatic colorectal cancer	Referred to OHMMG	SMC advice
Bosentan 62.5, 125mg film coated tablets (Tracleer®) - Non submission To reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease		Not recommended	SMC advice Bosentan was previously accepted in 2003 for restricted use in pulmonary arterial hypertension.
Clostridium botulinum neurotoxin Type A (Xeomin [®])	Blepharospasm and cervical dystonia	Pending specialist feedback	SMC advice
Dabigatran etexilate (Pradaxa [®])	Primary prevention of VTE in adults who have undergone elective total hip or total knee replacement surgery	Pending specialist feedback	SMC advice
Epoetin zeta (Retacrit [®])	Anaemia in patients with chronic renal failure	Not recommended Non -formulary medicine	Darbepoetin alfa (Aranesp®) and epoetin beta (NeoRecormon®) are the ESAs of choice locally <u>SMC advice</u> <u>SPC link</u>
Glucosamine hydrochloride (Alateris®)	Mild to moderate osteoarthritis of the knee	Not recommended	SMC advice
Lidocaine 70mg/tetracaine 70mg (Rapydan®) medicated plaster - Non submission Surface anaesthesia		Not recommended	SMC advice
Loteprednol etabonate 0.5% 5mg/ml (Lotemax [®] 0.5% Eye Drops) - Non submission	Post operative inflammation following ocular surgery	Not recommended	SMC advice
Nilotinib (Tasigna®) - Deferred advice	Chronic phase of Philadelphia positive chronic myelogenous leukaemia (CML)	Pending OHMMG decision	SMC advice
Panitumumab 20mg/ml concentrate for solution for infusion (Vectibix [®]) - Non submission	Metastatic colorectal carcinoma	Referred to OHMMG	SMC advice

Medicine	Indication	Local recommendation category	Comments and useful links
Perindopril arginine (Coversyl Arginine [®]) - <i>Abbreviated submission</i>	Essential hypertension, Symptomatic heart failure	Non-formulary medicine	SMC advice SPC link
Perindopril arginine/ indapamide (Coversyl Arginine Plus [®]) - Abbreviated submission	Essential hypertension	Non-formulary medicine	SMC advice SPC link
Teriparatide (Forsteo [®]) 20mcg/80mcl solution for injection - <i>Non submission</i>	Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk of fracture	Not recommended	SMC advice Teriparatide was previously accepted in 2004 for restricted use within a specialist treatment pathway for established severe osteoporosis in post-menopausal women

Click here for June 08 SMC briefing note

TAPG Update

	TAPG section	Drug(s)/topic	Changes
11.8	The Eye – Tear Substitutes	Carbomers	Liquivisc® discontinued and removed. Replaced by
			generic carbomer 980 0.2% eye drops.
12.1	Ear, Nose & Oropharynx – Drugs	Otitis externa	Betnesol-N [®] drops discontinued and removed.
	acting on the ear		Replaced by Betnesol® drops.
12.3	Ear, Nose & Oropharynx – Drugs	Oropharyngeal fungal	Nystatin (Nystan®) pastilles discontinued and
	acting on the oropharynx	infections	removed.

^{*}SMC accepted

Forthcoming SMC Advice

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website (www.nhstaysideadtc.scot.nhs.uk).